|
Gene: DNAH5 |
Gene summary for DNAH5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DNAH5 | Gene ID | 1767 |
Gene name | dynein axonemal heavy chain 5 | |
Gene Alias | CILD3 | |
Cytomap | 5p15.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q8TE73 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1767 | DNAH5 | C04 | Human | Oral cavity | OSCC | 2.09e-35 | 1.82e+00 | 0.2633 |
1767 | DNAH5 | C21 | Human | Oral cavity | OSCC | 7.14e-04 | 1.57e-01 | 0.2678 |
1767 | DNAH5 | SYSMH2 | Human | Oral cavity | OSCC | 4.32e-07 | 6.58e-01 | 0.2326 |
1767 | DNAH5 | SYSMH3 | Human | Oral cavity | OSCC | 5.39e-16 | 7.09e-01 | 0.2442 |
1767 | DNAH5 | SYSMH5 | Human | Oral cavity | OSCC | 1.09e-26 | 1.05e+00 | 0.0647 |
1767 | DNAH5 | HTA12-25-1 | Human | Pancreas | PDAC | 2.50e-03 | 4.72e-01 | 0.313 |
1767 | DNAH5 | HTA12-26-1 | Human | Pancreas | PDAC | 4.34e-14 | 7.27e-01 | 0.3728 |
1767 | DNAH5 | HTA12-29-1 | Human | Pancreas | PDAC | 6.09e-12 | 3.98e-01 | 0.3722 |
1767 | DNAH5 | HTA12-32-1 | Human | Pancreas | PDAC | 1.20e-02 | 7.98e-01 | 0.3624 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | EOLP: Erosive Oral lichen planus | |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00991113 | Oral cavity | OSCC | microtubule-based transport | 96/7305 | 190/18723 | 7.92e-04 | 4.27e-03 | 96 |
GO:0021591 | Oral cavity | OSCC | ventricular system development | 18/7305 | 29/18723 | 1.00e-02 | 3.49e-02 | 18 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501428 | Oral cavity | OSCC | Amyotrophic lateral sclerosis | 246/3704 | 364/8465 | 6.65e-21 | 1.11e-18 | 5.67e-19 | 246 |
hsa0501628 | Oral cavity | OSCC | Huntington disease | 204/3704 | 306/8465 | 1.70e-16 | 7.13e-15 | 3.63e-15 | 204 |
hsa0502228 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
hsa05014112 | Oral cavity | OSCC | Amyotrophic lateral sclerosis | 246/3704 | 364/8465 | 6.65e-21 | 1.11e-18 | 5.67e-19 | 246 |
hsa05016112 | Oral cavity | OSCC | Huntington disease | 204/3704 | 306/8465 | 1.70e-16 | 7.13e-15 | 3.63e-15 | 204 |
hsa05022112 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DNAH5 | SNV | Missense_Mutation | novel | c.6086N>T | p.Gly2029Val | p.G2029V | Q8TE73 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DNAH5 | SNV | Missense_Mutation | rs150601733 | c.1436N>A | p.Arg479His | p.R479H | Q8TE73 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DNAH5 | SNV | Missense_Mutation | rs749078502 | c.506N>T | p.Ser169Leu | p.S169L | Q8TE73 | protein_coding | tolerated(0.09) | benign(0.009) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DNAH5 | SNV | Missense_Mutation | rs776854779 | c.12076N>A | p.Glu4026Lys | p.E4026K | Q8TE73 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DNAH5 | SNV | Missense_Mutation | c.13643N>T | p.Arg4548Met | p.R4548M | Q8TE73 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DNAH5 | SNV | Missense_Mutation | c.11534N>A | p.Arg3845His | p.R3845H | Q8TE73 | protein_coding | tolerated(0.1) | possibly_damaging(0.608) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DNAH5 | SNV | Missense_Mutation | rs756069405 | c.8726N>A | p.Arg2909His | p.R2909H | Q8TE73 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-A5-A0GX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DNAH5 | SNV | Missense_Mutation | rs763063590 | c.9961N>T | p.Arg3321Trp | p.R3321W | Q8TE73 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DNAH5 | SNV | Missense_Mutation | rs774191944 | c.6268N>T | p.Arg2090Trp | p.R2090W | Q8TE73 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DNAH5 | SNV | Missense_Mutation | novel | c.11108A>G | p.Tyr3703Cys | p.Y3703C | Q8TE73 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |